Loading company
$1.240.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 27, 2026
Past performance
- 1W
- -69.7%
- 1M
- -71.0%
- 3M
- -77.7%
- 6M
- -73.7%
- 1Y
- -69.6%
$1.240.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 27, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Profit | -$25.8M | -$18M | -43.15% |
| Profit per share | -$0.20 | -$0.21 | +4.76% |
| Free Cash Flow | -$19.5K | -$15.5K | -26.22% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Zura Bio Ltd has no earnings call transcript available.
“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Zura Bio Ltd’s Item 2.02 8-K filed October 27, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.